Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

New data on NX-1207 show sustained symptomatic improvement in BPH

May 10, 2007

Spectrum cleared to add Canadian sites to BPH program for ozarelix

May 8, 2007

Target enrollment reached in phase IIb study of ozarelix for BPH

May 4, 2007

New therapeutic agents for benign prostatic hyperplasia disclosed in recent Ranbaxy patent

May 4, 2007

Vardenafil begins phase II study in patients with BPH / News in Context

May 3, 2007

YM-178: a selective beta3-adrenoceptor agonist for the treatment of overactive bladder

April 24, 2007

Anturol absorbed on bioequivalent basis from three application sites

April 23, 2007

First phase II study under way for cetrorelix for BPH

April 23, 2007

Uritos approved for overactive bladder in Japan

April 19, 2007

Renvela meets primary endpoint in hyperphosphatemic patients

April 18, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...